Search Results

Acurex Biosciences Corporation has been selected to present at the 15th annual Parkinson’s Disease Therapeutics Conference hosted by the Michael J. Fox Foundation.

Acurex Biosciences Corporation, a biopharmaceutical company with a mission to stop neurodegeneration before it begins, announces the appointment of renowned biopharmaceutical industry leader Dr. Robert Booth to its Board of Directors.

AcureX Therapeutics Corporation, a privately-held preclinical-stage biopharmaceutical company focused on developing potential disease altering therapeutics for neurodegenerative diseases, announced that it was selected to receive a grant from The Michael J. Fox Foundation to accelerate the development of AcureX’s biomarker for use in Parkinson’s disease drug development and clinical trials.

AcureX Therapeutics Corporation today announced that it was selected to present at the Oppenheimer Biotechnology – Emerging Science Summit on October 15th, 2021.

The Silverstein Foundation for Parkinson’s with GBA today announced grant funding to AcureX Therapeutics to support the development of novel, first in class, small molecule drug candidates for the treatment of Parkinson’s disease (PD).